Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.57 |
| ▸ | EIF4E | P06730 | 1/20 | 0.54 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.54 |
| ▸ | BECN1 | Q14457 | 6/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | KRAS | P01116 | 6/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.48 |
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10063472 | 0.71 | ESR1 (0.58) | NFE2L2EIF4EEIF4EBP1ESR1KRAS | |
| SCHEMBL278941 | 0.69 | CACNA1B (0.51) | KRAS | |
| SCHEMBL278801 | 0.68 | CACNA1B (0.51) | KRAS | |
| SCHEMBL24473539 | 0.68 | NTSR2 (0.61) | EIF4EEIF4EBP1ESR1 | |
| SCHEMBL19760420 | 0.67 | ESR1 (0.52) | NFE2L2BECN1ESR1KRASMDM2 | |
| Mibenratide SCHEMBL29534419 | 0.66 | ELANE (0.68) | — | |
| SCHEMBL24473663 | 0.65 | NTSR2 (0.61) | EIF4EEIF4EBP1 | |
| SCHEMBL17568833 | 0.65 | ESR1 (0.62) | NFE2L2EIF4EEIF4EBP1ESR1KRAS | |
| SCHEMBL24473339 | 0.65 | NTSR2 (0.73) | EIF4EEIF4EBP1 | |
| SCHEMBL24473602 | 0.65 | NTSR2 (0.71) | EIF4EEIF4EBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312649-A1 | MELANOCYTE-REGULATING PEPTIDES | IDP DISCOVERY PHARMA, S.L. (ES) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312649-A1 | MELANOCYTE-REGULATING PEPTIDES | MC1R, MITF, MCHR1 | NFE2L2 1937/4885EIF4E 3888/4885EIF4EBP1 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.